INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $8,821,000 | -8.2% | 609,166 | 0.0% | 0.08% | -2.6% |
| Q3 2017 | $9,613,000 | +27.1% | 609,166 | 0.0% | 0.08% | +18.2% |
| Q2 2017 | $7,566,000 | -23.6% | 609,166 | 0.0% | 0.07% | -18.5% |
| Q1 2017 | $9,899,000 | +7.7% | 609,166 | 0.0% | 0.08% | -10.0% |
| Q4 2016 | $9,192,000 | -1.0% | 609,166 | 0.0% | 0.09% | +7.1% |
| Q3 2016 | $9,284,000 | -60.7% | 609,166 | 0.0% | 0.08% | -66.1% |
| Q2 2016 | $23,648,000 | +39.6% | 609,166 | 0.0% | 0.25% | +38.5% |
| Q1 2016 | $16,935,000 | -48.3% | 609,166 | 0.0% | 0.18% | -33.9% |
| Q4 2015 | $32,767,000 | +34.3% | 609,166 | 0.0% | 0.27% | +20.4% |
| Q3 2015 | $24,391,000 | +632.9% | 609,166 | +484.8% | 0.22% | +675.9% |
| Q2 2015 | $3,328,000 | +33.8% | 104,166 | 0.0% | 0.03% | +38.1% |
| Q1 2015 | $2,487,000 | – | 104,166 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |